BIOMAT Database Logo BIOMAT Database Logo

Auranofin therapy for juvenile rheumatoid arthritis: results of the five-year open label extension trial. 1991

E H Giannini, and K S Barron, and C H Spencer, and D A Person, and J Baum, and B H Bernstein, and D W Kredich, and J C Jacobs, and L S Zemel, and D Gibbas
Division of Rheumatology, Children's Hospital Medical Center, Cincinnati, OH 45229.

Eighty-eight children with juvenile rheumatoid arthritis (JRA) who completed a double blind, randomized placebo controlled trial of oral gold were entered into an open label extension phase during which they received auranofin (AF) at a dosage of 0.15-0.2 mg/kg/day (9 mg/day maximum). Eleven (12.5%) patients completed 5 years of AF therapy; 77 (87.5%) did not. Fifteen (17%) of the 88 were in disease remission at the final visit. Mean duration of therapy for those who discontinued was 646 days. Parental/patient decision and insufficient therapeutic effect were the 2 most frequent reasons for early termination, followed by adverse effects. Though relatively well tolerated, AF provides adequate longterm management for only a small percentage of patients with JRA.

UI MeSH Term Description Entries
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006046 Gold A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D001171 Arthritis, Juvenile Arthritis in children, with onset before 16 years of age. The terms juvenile rheumatoid arthritis (JRA) and juvenile idiopathic arthritis (JIA) refer to classification systems for chronic arthritis in children. Only one subtype of juvenile arthritis (polyarticular-onset, rheumatoid factor-positive) clinically resembles adult rheumatoid arthritis and is considered its childhood equivalent. Arthritis, Juvenile Chronic,Arthritis, Juvenile Idiopathic,Arthritis, Juvenile Rheumatoid,Childhood Arthritis,PCJIA,PJIA Polyarticular Juvenile Idiopathic Arthritis,Polyarticular Juvenile Idiopathic Arthritis,Polyarticular-Course Juvenile Idiopathic Arthritis,Still's Disease, Juvenile-Onset,Enthesitis-Related Arthritis, Juvenile,Juvenile Chronic Arthritis,Juvenile Idiopathic Arthritis,Juvenile Rheumatoid Arthritis,Juvenile-Onset Still Disease,Juvenile-Onset Stills Disease,Oligoarthritis, Juvenile,Polyarthritis, Juvenile, Rheumatoid Factor Negative,Polyarthritis, Juvenile, Rheumatoid Factor Positive,Psoriatic Arthritis, Juvenile,Still Disease, Juvenile-Onset,Systemic Arthritis, Juvenile,Arthritides, Childhood,Arthritis, Childhood,Arthritis, Juvenile Enthesitis-Related,Arthritis, Juvenile Psoriatic,Arthritis, Juvenile Systemic,Childhood Arthritides,Chronic Arthritis, Juvenile,Enthesitis Related Arthritis, Juvenile,Idiopathic Arthritis, Juvenile,Juvenile Arthritis,Juvenile Enthesitis-Related Arthritis,Juvenile Oligoarthritis,Juvenile Onset Still Disease,Juvenile Onset Stills Disease,Juvenile Psoriatic Arthritis,Juvenile Systemic Arthritis,Juvenile-Onset Still's Disease,Rheumatoid Arthritis, Juvenile,Still Disease, Juvenile Onset,Still's Disease, Juvenile Onset,Stills Disease, Juvenile-Onset
D001310 Auranofin An oral chrysotherapeutic agent for the treatment of rheumatoid arthritis. Its exact mechanism of action is unknown, but it is believed to act via immunological mechanisms and alteration of lysosomal enzyme activity. Its efficacy is slightly less than that of injected gold salts, but it is better tolerated, and side effects which occur are potentially less serious. Crisinor,Ridaura,Ridauran,SK&F D 39162,SK&F-39162,SK&F 39162,SK&F39162

Related Publications

E H Giannini, and K S Barron, and C H Spencer, and D A Person, and J Baum, and B H Bernstein, and D W Kredich, and J C Jacobs, and L S Zemel, and D Gibbas
Auranofin in juvenile rheumatoid arthritis. An open label, non-controlled study.
June 1984, Clinical rheumatology,
E H Giannini, and K S Barron, and C H Spencer, and D A Person, and J Baum, and B H Bernstein, and D W Kredich, and J C Jacobs, and L S Zemel, and D Gibbas
Longterm auranofin therapy in patients with juvenile rheumatoid arthritis.
August 1986, The Journal of rheumatology,
E H Giannini, and K S Barron, and C H Spencer, and D A Person, and J Baum, and B H Bernstein, and D W Kredich, and J C Jacobs, and L S Zemel, and D Gibbas
Auranofin in the treatment of juvenile rheumatoid arthritis.
January 1983, The Journal of pediatrics,
E H Giannini, and K S Barron, and C H Spencer, and D A Person, and J Baum, and B H Bernstein, and D W Kredich, and J C Jacobs, and L S Zemel, and D Gibbas
An European open multicentre trial with auranofin in rheumatoid arthritis.
March 1984, Clinical rheumatology,
E H Giannini, and K S Barron, and C H Spencer, and D A Person, and J Baum, and B H Bernstein, and D W Kredich, and J C Jacobs, and L S Zemel, and D Gibbas
Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema.
November 2009, Ophthalmology,
E H Giannini, and K S Barron, and C H Spencer, and D A Person, and J Baum, and B H Bernstein, and D W Kredich, and J C Jacobs, and L S Zemel, and D Gibbas
An open trial of auranofin (oral gold preparation) in rheumatoid arthritis.
September 1986, The Journal of the Association of Physicians of India,
E H Giannini, and K S Barron, and C H Spencer, and D A Person, and J Baum, and B H Bernstein, and D W Kredich, and J C Jacobs, and L S Zemel, and D Gibbas
Auranofin therapy in rheumatoid arthritis.
August 1982, The Journal of laboratory and clinical medicine,
E H Giannini, and K S Barron, and C H Spencer, and D A Person, and J Baum, and B H Bernstein, and D W Kredich, and J C Jacobs, and L S Zemel, and D Gibbas
Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial.
March 2021, Arthritis & rheumatology (Hoboken, N.J.),
E H Giannini, and K S Barron, and C H Spencer, and D A Person, and J Baum, and B H Bernstein, and D W Kredich, and J C Jacobs, and L S Zemel, and D Gibbas
Early experiences with auranofin in juvenile rheumatoid arthritis.
December 1983, The American journal of medicine,
E H Giannini, and K S Barron, and C H Spencer, and D A Person, and J Baum, and B H Bernstein, and D W Kredich, and J C Jacobs, and L S Zemel, and D Gibbas
Auranofin therapy in juvenile rheumatoid arthritis: a 48-week phase II study.
January 1986, Scandinavian journal of rheumatology. Supplement,
Copied contents to your clipboard!